Candidemia is associated with high mortality rate especially in critically ill (ICU) patients with septic shock and echinocandins such as anidulafungin are recommended as first line treatment. Available pharmacokinetic studies of anidulafungin in healthy volunteers and in patients with renal or hepatic impairment showed that no dose adjustment is needed even in patients receiving standard intermittent haemodialysis. However, few data are available with continuous veno-venous haemofiltration (CVVH). In this study the pharmacokinetic of anidulafungin was studied in two ICU patients with candidemia and septic shock undergoing CVVH. Both patients had satisfactory parameters of Cmax (9.04 mg/L and 5.68 mg/L, respectively), AUC (95.18 mg/L*h and 67.48 mg/L*h) and Cmin (2.61 mg/L and 1.43 mg/L). AUC/MIC ratio and Cmax/MIC values were: 11887 and 8435; 1130,25 and 710, for patient 1 and 2 respectively. Our data confirm that in patients with septic shock anidulafungin presents only mild pharmacokinetic changes compared to data reported during CVVH alone.
Introduction 1
Bloodstream infections caused by Candida spp. are associated with a mortality of 30-2 50%, especially in intensive care units (ICU), where the risk of invasive Candida 3 infection is increased 1 . Echinocandins such as anidulafungin are fungicidal against 4
Candida spp. and are recommended as first line agents by the IDSA and ESCMID 5 guidelines [1] [2] [3] . Anidulafungin has no known metabolism and undergoes spontaneous 6 degradation at physiologic pH and temperature 4 and pharmacokinetic studies in healthy 7 volunteers and in patients with renal or hepatic impairment demonstrated that no dose 8 change is needed, also including patients undergoing standard intermittent 9 haemodialysis [5] [6] . 10
In patients with septic shock the pharmacokinetic of antimicrobials may dramatically 11 change owing to tissue perfusion, change of protein binding, drug clearance and fluid 12 overload which may increase the volume of distribution of many drugs 4 . Continuous 13 veno-venous haemofiltration (CVVH) is frequently used in ICU patients with renal 14 failure and the pharmacokinetic of antifungals may be altered, according to various 15 parameters both patient-related and extracorporeal circuit-related, such as the ultrafiltrate 16 and dialysate rates, dialysate concentrations and the type of membranes. 17
There are very few data on pharmacokinetic of anidulafungin in ICU patients, either with 18 septic shock or CVVH. The aim of this study was to describe the pharmacokinetics of 19 anidulafungin in two ICU patients with septic shock during CVVH. 20 21
Material and methods 22
Anidulafungin plasmatic concentrations were studied in two ICU patients with septic 23 shock, receiving CVVH and treated with standard dosage (100 mg/die preceded by 24 loading dose of 200 mg, 1 hour of infusion) for candidemia. The area under the curve 25 Massachusetts, USA). A non-compartmental steady state model was used. 10
The patients main clinical, microbiological and laboratory data are illustrated in Table 1 . 11
Notably, patient 2 was receiving tacrolimus and cyclosporine because of heart transplant. 12
13

Results
14
Patients' clinical and microbiological characteristics are illustrated in Table 1 Available data in non-ICU population pharmacokinetic analysis for anidulafungin show 7 that pharmacokinetic parameters associated with success include AUC at steady state >35 8 mg/L*h and minimum plasma concentration at steady state (C min ) >1 mg/L 6 . The 9 strongest relationship with antifungal effect in animal models, considering the 10 pharmacokinetic/ pharmacodynamic parameters, was observed with AUC/MIC ratio of 11 250 and C max /MIC > 4 5, 9 . 12 Our patients did achieve AUC/MIC >250 and C max /MIC > 4, perhaps due also to the very 13 low MIC of C. albicans tested. These results underscore that even in patients with septic 14 shock receving CVVH anidulafungin has a very good pharmacokinetic profile. with anidulafungin before microbiological confirmation of candidemia and plenty 1 satisfaction of pharmacokinetic parameters, both patients were dead at 21 days after 2 diagnosis, with negative blood cultures at 48 hours after diagnosis. 3
To our knowledge there are few data on pharmacokinetic of anidulafungin in ICU 4 patients and no data are available in patients with septic shock undergoing CVVH. A case 5 report in the ICU setting by Burkhardt reported that anidulafungin does not necessitate 6 dose adjustment with septic shock undergoing extended daily dialysis 10 . However, 7 pharmacokinetic parameters were only studied at the first day of treatment, when the 8 loading dose was administered: C max , C min and AUC values were 5.32 mg/L, 1.60 mg/L 9 and 55.2 mg *h/L, respectively. Leitner et al. described 10 patients receiving CVVH, 10 three of which with septic shock, with a CVVH ultrafiltration rate of 1500 ml/h, an 11 extended 3-h anidulafungin loading dose infusion and 1.5-h infusion mainteinance dose 12 11 . C max values were evaluated at day 1, 2 and 3 whilst AUC was determined only during 13 the first day. This study reported a mean C max of 5.9+ 2 mg/L at day 3 and a mean arterial 14 AUC of 109.9+ 49.82 mg*h/L at day 1. According to these data, the Authors concluded 15 that dose changes are not needed during CVVH. 16
In conclusion, anidulafungin treatment of ICU patients with septic shock and CVVH did 17 confirm that no dose changes are needed compared to patients treated with CVVH alone. 
